Skip to main content

Table 2 Multivariable mixed-effect regression associated group pMDA with worse 5-year functionality (HAQ) trajectory than pRLDA group

From: Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group

HAQ multivariable analysis Coefficient 95% CI p value
Group pMDA (vs pRLDA) + 0.28 + 0.18 to + 0.39 p < 0.0001*
Gender female (vs male) + 0.13 + 0.04 to + 0.23 p = 0.008*
Age (per year) + 0.009 + 0.006 to + 0.012 p < 0.0001*
Disease duration (per year) + 0.004 − 0.001 to + 0.009 p = 0.092
Time 3–9 months (vs baseline) − 0.203 − 0.279 to − 0.126 p < 0.0001*
Time 9–15 months (vs baseline) − 0.289 − 0.366 to − 0.212 p < 0.0001*
Time 15–21 months (vs baseline) − 0.288 − 0.364 to − 0.213 p < 0.0001*
Time 21–27 months (vs baseline) − 0.285 − 0.362 to − 0.208 p < 0.0001*
Time 27–33 months (vs baseline) − 0.347 − 0.432 to − 0.261 p < 0.0001*
Time 33–42 months (vs baseline) − 0.326 − 0.399 to − 0.254 p < 0.0001*
Time 42–54 months (vs baseline) − 0.323 − 0.396 to − 0.251 p < 0.0001*
Time 54–60 months (vs baseline) − 0.375 − 0.448 to − 0.303 p < 0.0001*
  1. *Variable is associated significantly with patients’ 5-year functionality (HAQ) course (p < 0.05 significance threshold)
  2. Regression coefficient that represents increase (+) or decrease (−) in 5-year functionality (HAQ) course associated with the variable (category membership for categorical variable or unit increase for continuous variable)
  3. Efficiency of multivariable analysis: RMSE (Root mean square error) = 0.352, R2 (R-squared) = 0.573
  4. pRLDA persistent remission/low disease activity group; pMDA persistent moderate disease activity group
\